Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Change in Receivables (2021 - 2025)

Keros Therapeutics' Change in Receivables history spans 5 years, with the latest figure at $75000.0 for Q4 2025.

  • For Q4 2025, Change in Receivables fell 96.81% year-over-year to $75000.0; the TTM value through Dec 2025 reached $825000.0, down 68.26%, while the annual FY2025 figure was $825000.0, 68.26% down from the prior year.
  • Change in Receivables reached $75000.0 in Q4 2025 per KROS's latest filing, up from -$12.3 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $18.0 million in Q4 2021 to a low of -$18.0 million in Q1 2022.
  • Average Change in Receivables over 5 years is $274384.6, with a median of $83000.0 recorded in 2024.
  • The largest YoY upside for Change in Receivables was 17428.92% in 2025 against a maximum downside of 3309.38% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $18.0 million in 2021, then tumbled by 200.0% to -$18.0 million in 2022, then surged by 100.79% to $143000.0 in 2023, then surged by 1546.15% to $2.4 million in 2024, then tumbled by 96.81% to $75000.0 in 2025.
  • Per Business Quant, the three most recent readings for KROS's Change in Receivables are $75000.0 (Q4 2025), -$12.3 million (Q3 2025), and -$1.5 million (Q2 2025).